Robert M. Janosky
Corporate Officer/Principal chez SATSUMA PHARMACEUTICALS, INC.
Profil
Robert M.
Janosky is currently the Chief Commercial Officer at Satsuma Pharmaceuticals, Inc. Prior to this, he worked as the VP of Business Development & Strategic Planning at DURECT Corp.
from 2016 to 2020.
He received his undergraduate degree from the University of Vermont and his MBA from the University of Rochester Simon Business School.
Postes actifs de Robert M. Janosky
| Sociétés | Poste | Début |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05/03/2020 |
Anciens postes connus de Robert M. Janosky
| Sociétés | Poste | Fin |
|---|---|---|
| DURECT CORPORATION | Corporate Officer/Principal | 01/03/2020 |
Formation de Robert M. Janosky
| University of Vermont | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
